RxDoctor Payments Data

Darren Oneill, MD

Internal Medicine · Enfield, CTNPI 1861434607

Payments from drug & device makers

$443in general payments, 2019–2025

Across 25 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$192
  • AbbVie$65
  • Novo Nordisk$47
  • Boehringer Ingelheim$32
  • Sunovion Pharmaceuticals Inc.$27
  • Sumitomo Pharma America, Inc.$23
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$42997%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$443 in reported general payments places this provider in the 65th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$409,584
Medicare patients
746
Services billed
4,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban395$368,012
MounjaroTirzepatide208$226,247
TrulicityDulaglutide139$146,716
JardianceEmpagliflozin137$129,012
JanuviaSitagliptin Phosphate111$125,711
OzempicSemaglutide99$118,434
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$73,517
XareltoRivaroxaban45$45,206
FarxigaDapagliflozin Propanediol33$38,103
JanumetSitagliptin Phos/Metformin Hcl16$23,171
Breo ElliptaFluticasone/Vilanterol36$18,036
Aimovig AutoinjectorErenumab-Aooe20$14,762
Atorvastatin Calcium1,198$13,872
BrilintaTicagrelor12$9,705
Omeprazole723$9,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$368,012395 claims
Boehringer IngelheimJardiance$32$129,012137 claims
Novo NordiskOzempic$47$118,43499 claims
AbbVieLinzess, Synthroid$65$15,06891 claims
Sumitomo Pharma America, Inc.Gemtesa$23$8,07816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →